Lilly touts topline late-phase data for once-weekly insulin in race to enter US market
As Novo Nordisk stares down an FDA adcomm later this month to discuss its once-weekly insulin, Eli Lilly is working on its own, sharing positive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
